167 related articles for article (PubMed ID: 37658026)
1. [Pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory (R/R) Mantle Cell Lymphoma].
Fileni C; Sarkozy C
Bull Cancer; 2023 Oct; 110(10):988-990. PubMed ID: 37658026
[No Abstract] [Full Text] [Related]
2. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Eyre TA; Shah NN; Dreyling M; Jurczak W; Wang Y; Cheah CY; Song Y; Gandhi M; Chay C; Sharman J; Andorsky DJ; Messersmith HM; Ruppert AS; Muthig VA; Ito R; Wang ML
Future Oncol; 2022 Nov; 18(36):3961-3969. PubMed ID: 36377973
[TBL] [Abstract][Full Text] [Related]
3. Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
Davis DD; Ohana Z; Pham HM
J Oncol Pharm Pract; 2024 Jan; 30(1):182-188. PubMed ID: 38043933
[TBL] [Abstract][Full Text] [Related]
4. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR; Shah NN; Jurczak W; Cheah CY; Pagel JM; Woyach JA; Fakhri B; Eyre TA; Lamanna N; Patel MR; Alencar A; Lech-Maranda E; Wierda WG; Coombs CC; Gerson JN; Ghia P; Le Gouill S; Lewis DJ; Sundaram S; Cohen JB; Flinn IW; Tam CS; Barve MA; Kuss B; Taylor J; Abdel-Wahab O; Schuster SJ; Palomba ML; Lewis KL; Roeker LE; Davids MS; Tan XN; Fenske TS; Wallin J; Tsai DE; Ku NC; Zhu E; Chen J; Yin M; Nair B; Ebata K; Marella N; Brown JR; Wang M
Lancet; 2021 Mar; 397(10277):892-901. PubMed ID: 33676628
[TBL] [Abstract][Full Text] [Related]
5. [New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].
Rousseau A; Thieblemont C
Bull Cancer; 2021 Feb; 108(2):142-144. PubMed ID: 33531153
[No Abstract] [Full Text] [Related]
6. [Ibrutinib prescription in B-cell lymphoid neoplasms].
Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
[TBL] [Abstract][Full Text] [Related]
7. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Owen C; Berinstein NL; Christofides A; Sehn LH
Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
[TBL] [Abstract][Full Text] [Related]
8. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
[TBL] [Abstract][Full Text] [Related]
9. Pirtobrutinib: First Approval.
Keam SJ
Drugs; 2023 Apr; 83(6):547-553. PubMed ID: 37004673
[TBL] [Abstract][Full Text] [Related]
10. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML; Jurczak W; Zinzani PL; Eyre TA; Cheah CY; Ujjani CS; Koh Y; Izutsu K; Gerson JN; Flinn I; Tessoulin B; Alencar AJ; Ma S; Lewis D; Lech-Maranda E; Rhodes J; Patel K; Maddocks K; Lamanna N; Wang Y; Tam CS; Munir T; Nagai H; Hernandez-Ilizaliturri F; Kumar A; Fenske TS; Seymour JF; Zelenetz AD; Nair B; Tsai DE; Balbas M; Walgren RA; Abada P; Wang C; Zhao J; Mato AR; Shah NN
J Clin Oncol; 2023 Aug; 41(24):3988-3997. PubMed ID: 37192437
[TBL] [Abstract][Full Text] [Related]
11. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.
Thompson PA; Tam CS
Blood; 2023 Jun; 141(26):3137-3142. PubMed ID: 37156004
[TBL] [Abstract][Full Text] [Related]
12. Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.
De SK
Curr Med Chem; 2023 Oct; ():. PubMed ID: 37818564
[TBL] [Abstract][Full Text] [Related]
13. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA
N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157
[TBL] [Abstract][Full Text] [Related]
14. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y; Che Y; Chen Z; Vargas J; Badillo M; Bigcal JN; Lee HH; Wang W; Yao Y; Nie L; Flowers CR; Wang M
J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719376
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Walter HS; Rule SA; Dyer MJ; Karlin L; Jones C; Cazin B; Quittet P; Shah N; Hutchinson CV; Honda H; Duffy K; Birkett J; Jamieson V; Courtenay-Luck N; Yoshizawa T; Sharpe J; Ohno T; Abe S; Nishimura A; Cartron G; Morschhauser F; Fegan C; Salles G
Blood; 2016 Jan; 127(4):411-9. PubMed ID: 26542378
[TBL] [Abstract][Full Text] [Related]
16. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe.
Aydilek E; Wulf G; Schwarz F; Bacher U; Rummel M; Stiefel O; Kerkhoff A; Maulhardt M; Melchardt T; Pabst T; Lenz G; Shumilov E
Cancer Med; 2024 May; 13(10):e7289. PubMed ID: 38770551
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.
Telaraja D; Kasamon YL; Collazo JS; Leong R; Wang K; Li P; Dahmane E; Yang Y; Earp J; Grimstein M; Rodriguez LR; Theoret MR; Gormley NJ
Clin Cancer Res; 2024 Jan; 30(1):17-22. PubMed ID: 37624619
[TBL] [Abstract][Full Text] [Related]
19. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Mato AR; Woyach JA; Brown JR; Ghia P; Patel K; Eyre TA; Munir T; Lech-Maranda E; Lamanna N; Tam CS; Shah NN; Coombs CC; Ujjani CS; Fakhri B; Cheah CY; Patel MR; Alencar AJ; Cohen JB; Gerson JN; Flinn IW; Ma S; Jagadeesh D; Rhodes JM; Hernandez-Ilizaliturri F; Zinzani PL; Seymour JF; Balbas M; Nair B; Abada P; Wang C; Ruppert AS; Wang D; Tsai DE; Wierda WG; Jurczak W
N Engl J Med; 2023 Jul; 389(1):33-44. PubMed ID: 37407001
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
McCulloch R; Visco C; Eyre TA; Frewin R; Phillips N; Tucker DL; Quaglia FM; McMillan A; Lambert J; Crosbie N; Rule S
Br J Haematol; 2020 May; 189(4):684-688. PubMed ID: 32011729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]